文献速递自身炎症与 IgG4 相关病

成人起病Still病一线生物制剂与传统合成改善病情抗风湿药治疗的比较:一项多中心、回顾性、倾向加权队列研究

First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study.
PubMed 文献 · Lancet Rheumatol · 2025-03-28

这项在德国16个中心开展的多中心回顾性倾向加权队列研究纳入86例活动期成人起病Still病患者,比较一线生物制剂与传统合成改善病情抗风湿药(csDMARD)的疗效。一线生物制剂组达到持续无事件缓解的可能性更高(OR 7.20,95%CI 2.50-36.64;p=0.0007),第72周持续无事件缓解率为50%对12%,且糖皮质激素相关并发症更少。

要点

  • 一线生物制剂组达到持续无事件缓解的OR为7.20(95%CI 2.50-36.64;p=0.0007)。
  • 第72周持续无事件缓解率:一线生物制剂组50%(95%CI 34-65%;n=21)vs 一线csDMARD组12%(95%CI 3-23%;n=5)。
  • 一线csDMARD组报告糖皮质激素相关并发症(新发动脉高血压n=2、糖皮质激素相关皮肤病n=3),生物制剂组无。

核心结论

  • 成人起病Still病患者一线生物制剂治疗与持续无事件缓解呈统计学显著关联,且并发症更少。
  • 作者认为,与传统治疗选择相比,生物制剂在成人起病Still病中具有改善患者结局的潜力。

研究设计与样本

  • 多中心、回顾性、倾向加权队列研究,在德国16个二级和三级风湿病中心开展。
  • 纳入86例符合山口分类标准、有活动性疾病且当前未治疗的患者,所有患者均有第12周和第72周随访评估记录。
  • 采用倾向评分加权逻辑回归分析,平衡两组间初始Pouchot评分、铁蛋白浓度、年龄和性别差异,分析基于符合方案人群。
  • 研究注册于ISRCTN registry,注册号ISRCTN86135778;研究未涉及有生活经验的人参与设计。

主要发现

  • 2007年1月1日至2022年9月30日筛查228例患者,排除142例,纳入86例成人起病Still病患者(新发诊断或发作且无任何维持治疗包括糖皮质激素)。
  • 86例中女性50例(58%)、男性36例(42%),白人84例(98%);纳入时平均年龄39.4岁(SD 15.4)。
  • 44例(51%)接受一线生物制剂,42例(49%)接受一线传统合成改善病情抗风湿药。
  • 一线生物制剂治疗与达到主要终点持续无事件缓解的可能性更高相关(OR 7.20,95%CI 2.50-36.64;p=0.0007)。
  • 第72周持续无事件缓解率:一线生物制剂组50%(95%CI 34-65%;n=21)vs 一线传统合成组12%(95%CI 3-23%;n=5);一线传统合成组报告糖皮质激素相关并发症(新发动脉高血压n=2、糖皮质激素相关皮肤病n=3),生物制剂组无;传统合成组42例中3例(7%)死亡(2例噬血细胞性淋巴组织细胞增生症,1例原因不明),生物制剂组无死亡。

关键数值与推荐

  • 主要终点为持续无事件缓解,即持续缓解(C反应蛋白<10 mg/L且无关节炎、皮疹或发热)与随访期间无并发症的复合终点。
  • 纳入标准为诊断为成人起病Still病、符合山口分类标准、有活动性疾病且当前未治疗。
  • 一线生物制剂组第72周持续无事件缓解率50%(95%CI 34-65%;n=21),一线传统合成组12%(95%CI 3-23%;n=5)。

临床怎么用

  • 作者认为,一线生物制剂治疗在成人起病Still病患者中与持续无事件缓解和更少并发症呈统计学显著关联。
  • 作者指出,研究结果凸显生物制剂相较于传统治疗选择在成人起病Still病中改善患者结局的潜力。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data on the efficacy of biological disease-modifying antirheumatic drug (DMARD) therapies such as anakinra, canakinumab, and tocilizumab as a primary therapeutic option in adult-onset Still's disease (AOSD) are scarce, and treatment recommendations rely mainly on data extrapolated from paediatric studies. The aim of this study was to compare the effectiveness of first-line biological DMARD therapy versus conventional synthetic DMARD therapy in AOSD. METHODS: This multicentre, retrospective, propensity weighted cohort study was done at 16 secondary and tertiary rheumatology centres across Germany. Eligible patients were diagnosed with AOSD, met the Yamaguchi classification criteria, and had active disease without current treatment. All patients had documented follow-up assessments at weeks 12 and 72. The primary endpoint was sustained, event-free remission; a combined endpoint of sustained remission (C-reactive protein <10 mg/L and no arthritis, rash, or fever) and absence of complications during follow up in patients treated with first-line biological DMARDs (with or without glucocorticoids) or conventional synthetic DMARDs (methotrexate or glucocorticoids). Analysis was by propensity score weighted logistic regression, thereby balancing for the initial Pouchot score, ferritin concentration, and age and sex differences between groups. Analysis was done in the per protocol population. People with lived experience were not involved in the study design. The study is registered with the ISRCTN registry, ISRCTN86135778. FINDINGS: Between Jan 1, 2007, and Sep 30, 2022, we screened 228 patients for inclusion. 142 patients were excluded, and 86 patients with AOSD who had an incident diagnosis or a flare without any maintenance treatment including glucocorticoids were enrolled and included in our analysis. 50 (58%) of 86 patients were female, 36 (42%) were male, and 84 (98%) were White. The mean age at inclusion was 39·4 years (SD 15·4). 44 (51%) of 86 had received a first-line biological DMARD and 42 (49%) received a first-line conventional synthetic DMARD. Biological DMARD therapy was associated with a greater likelihood of reaching the primary endpoint of sustained, event-free remission (OR 7·20, 95% CI 2·50-36·64; p=0·0007). At week 72, the rate of sustained, event-free remission was 50% (95% CI 34-65%; n=21) in the first-line biological DMARD group and 12% (3-23%; n=5) in the first-line conventional synthetic group. Glucocorticoid-related complications were more often described in the first-line conventional synthetic DMARD group (new-onset arterial hypertension [n=2] and glucocorticoid-related skin diseases [n=3]) versus none in the first-line biological DMARD group). Three (7%) of 42 patients in the conventional synthetic DMARD group died (two from macrophage activation syndrome, one unknown cause) versus none in the first-line biological DMARD group. INTERPRETATION: First-line biological DMARD therapy in patients with AOSD showed a statistically significant association with sustained, event-free remission and fewer complications. Our findings highlight the potential of biologics to improve patient outcomes compared with conventional treatment options in AOSD. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Kernder A, Filla T, Friedrich R, et al. First-line biological versus conventional synthetic disease-modifying antirheumatic drug therapy in adult-onset Still's disease: a multicentre, retrospective, propensity weighted cohort study. Lancet Rheumatol. 2025. PMID: 40164168. doi:10.1016/S2665-9913(25)00023-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。